This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Top 5 Must-Follow Earnings for Monday

NEW YORK ( TheStreet) -- Another week into earnings season and Wall Street is still moving at full speed. Here is what to watch on Monday.

Vivus (VVUS - Get Report)

Who They Are: Vivus is a biopharmaceutical company developing innovative, next-generation therapies to address unmet needs in obesity, diabetes and sexual health. Vivus trades an average of 14.1 million shares per day with a marketcap of $2.2 billion.

VVUS Chart VVUS data by YCharts

Vivus is forecast to record shallow second-quarter earnings after the market closes July 30. The consensus estimate is currently a loss of 23 cents a share, another drop of three cents from a loss of 20 cents during the equivalent quarter last year.

Analyst opinion is mixed with this company. Most of the analysts surveyed don't believe a buy or a sell is currently warranted. Right now, Vivus has five buy recommendations out of 11 analysts covering the company, six holds, and no analysts recommend selling.

Four out of 11 analysts now rate Vivus a strong buy down from five analysts a month ago. Compared to three months ago, fewer analysts are rating this company as a strong buy. The stock has appreciated 180% in the last year, and the average analyst target price for Vivus is $38.29.

It's not a typo, Vivus really is up 180% and it was on my radar a lot.

The last date Vivus released earnings was May 7, and the closing price before earnings was $23.58. Based on Tuesday's closing price of $23, shares are down 2.5%.

The bottom line has falling earnings year-over-year with a loss of $46.14 million last fiscal year compared to an even bigger loss of $66.07 million in the previous year.

With 15% short interest, investors better know what they are doing before picking this one up -- 15% is the sweet spot for short interest as a bearish indicator. I like what they do as a company, but I would avoid the stock as an investment at this level. The earnings release may not have much of an impact either way because of the binary reaction pharmaceuticals have to trial results.

1 of 5

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG
STX $51.79 -0.46%
APC $83.86 1.27%
FST $0.20 -4.76%
MAS $26.07 -2.36%
VVUS $2.35 -4.47%

Markets

DOW 17,698.18 -77.94 -0.44%
S&P 500 2,059.69 -8.20 -0.40%
NASDAQ 4,880.2280 -20.6570 -0.42%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs